Drugs / TAVO103A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05313152 | Apr 2022 → Apr 2023 | — | Tavotek Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAVO103A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05313152 ↗ |
| Route | Intravenous | “TAVO103A single ascending dose IV infusion.” NCT05313152 ↗ |